Transient ischemic attack, also known as a mini stroke, is characterized by a temporary blockage of blood flow to the brain. It can cause stroke-like symptoms, lasting for a few minutes to a few hours. Various studies indicate the annual incidence of transient ischemic attack to be about 0.42 to 1.22 per 1000 person-years, with the incidence increasing with age. The growing cases of transient ischemic attacks are highlighting the need for new drugs that can address the underlying causes and reduce the risk of progression.
Major companies involved in the transient ischemic attack pipeline drugs market include Janssen Research & Development, LLC and Bayer, among others.
Leading drugs currently under the pipeline include Asundexian (BAY2433334) and Milvexian, among others.
The increasing prevalence of transient ischemic attacks and the growing focus on secondary prevention strategies are expected to accelerate the development of new therapeutic agents.
The Transient Ischemic Attack Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into transient ischemic attack drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for transient ischemic attack. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The transient ischemic attack pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from transient ischemic attack.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to transient ischemic attack.
Transient ischemic attack causes a temporary disruption in the blood supply to a part of the brain. The transient episode of neurological dysfunction can resolve within minutes to hours. Transient ischemic attack needs prompt treatment as it indicates a warning sign of a possible future stroke. Common symptoms include a dropped face, weakness or numbness in one arm, slurred speech, and dizziness, among others.
Treatment for a transient ischemic attack consists of medication like statins and blood thinners that can help prevent a further episode. Popular anticoagulants include edoxaban, apixaban, dabigatran, warfarin, and rivaroxaban. However, the risk of bleeding remains a significant side effect for all anticoagulants. Thus, the limited availability of targeted and effective treatments with a better safety profile reflects a gap in patient care, which can be bridged through the development of more specialized drugs in the pipeline.
This section of the report covers the analysis of transient ischemic attack drugs based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials for transient ischemic attacks.
The drug molecule categories covered under the transient ischemic attack pipeline analysis include small molecules, peptides, oligonucleotides, and biologics. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for transient ischemic attacks.
The EMR report for the transient ischemic attack drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in transient ischemic attack clinical trials:
Major drugs currently in the drug pipeline are as follows:
Sponsored by Bayer, the objective of this Phase III, multicenter, placebo-controlled clinical trial is to evaluate the efficacy of oral FXIa inhibitor, asundexian, for the prevention of ischemic stroke in male and female participants (aged 18 years and above) following a high-risk transient ischemic attack or acute non-cardioembolic ischemic stroke. The study is expected to be completed by October 2025 and has around 12300 participants.
Janssen Research & Development, LLC is conducting a Phase III clinical trial aimed at investigating the safety and efficacy of milvexian (an oral factor XIa inhibitor) compared to placebo for stroke prevention after a high-risk transient ischemic attack or an acute ischemic stroke. The interventional study has enrolled an estimated 15000 subjects and is expected to be completed by December 2026.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Transient Ischemic Attack Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for transient ischemic attack. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within transient ischemic attack pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share